US 12,435,063 B2
Nitrogen containing heterocycles as CDK12 inhibitors
Koji Ono, Kanagawa (JP); Masahiro Ito, Kanagawa (JP); Toshio Tanaka, Kanagawa (JP); Moriteru Asano, Kanagawa (JP); Takaharu Hirayama, Kanagawa (JP); Jun Fujimoto, Kanagawa (JP); Nobuki Sakauchi, Kanagawa (JP); Yasuhiro Hirata, Kanagawa (JP); Akinori Toita, Kanagawa (JP); Nao Morishita, Kanagawa (JP); Hironori Kokubo, Kanagawa (JP); Yasuhiro Imaeda, Kanagawa (JP); Hironobu Maezaki, Kanagawa (JP); Douglas Robert Cary, Kanagawa (JP); Ryo Mizojiri, Kanagawa (JP); Nobuo Cho, Kanagawa (JP); Hiroshi Banno, Kanagawa (JP); Hidekazu Tokuhara, Kanagawa (JP); and Yasuyoshi Arikawa, Kanagawa (JP)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Dec. 6, 2022, as Appl. No. 18/075,853.
Application 18/075,853 is a continuation of application No. 17/042,394, granted, now 11,584,737, previously published as PCT/JP2019/013531, filed on Mar. 28, 2019.
Claims priority of application No. JP2018-063740 (JP), filed on Mar. 29, 2018.
Prior Publication US 2023/0117295 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61P 35/00 (2006.01); C07D 213/84 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 471/10 (2006.01); C07D 487/10 (2006.01); C07D 495/10 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/00 (2018.01); C07D 213/84 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 471/10 (2013.01); C07D 487/10 (2013.01); C07D 495/10 (2013.01)] 15 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Chemistry
wherein
X is CH or N;
R1 is an optionally substituted C1-6 alkyl group, an optionally substituted C1-6 alkoxy group, an optionally substituted C6-14 aryl group, an optionally substituted heterocyclic group, or —NR2R3;
R2 is a hydrogen atom or a substituent;
R3 is a substituent;
ring A is an optionally further substituted aromatic ring;
ring B is an optionally further substituted cyclohexane ring;
ring C is an optionally further substituted 6-membered nitrogen-containing aromatic heterocycle,
or a salt thereof, or a hydrate thereof, or a solvate thereof.